You are here:

Forthcoming Submissions:

PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
afamelanotide (Scenesse) Clinuvel (UK) Ltd Full submission 1/05/2017 Q3 2017 Q3 2017
cabozantinib (Cabometyx) Ipsen Ltd Full submission 6/03/2017 2/05/2017 12/06/2017
carfilzomib (Kyprolis) Amgen Ltd Full submission 3/04/2017 Q3 2017 Q3 2017
ibrutinib (Imbruvica) Janssen-Cilag Ltd Resubmission 6/02/2017 7/03/2017 10/04/2017
idebenone (Raxone) Santhera Pharmaceuticals Full submission 6/02/2017 4/04/2017 8/05/2017
liposomal irinotecan (Onivyde) Baxalta Full submission 5/12/2016 7/02/2017 13/03/2017
nivolumab (Opdivo) for Hodgkin lymphoma Bristol-Myers Squibb Pharmaceuticals Ltd Full submission 3/04/2017 Q2 2017 Q3 2017
nivolumab (Opdivo) for RCC Bristol-Myers Squibb Pharmaceuticals Ltd Resubmission 6/03/2017 2/05/2017 12/06/2017
obeticholic acid (Ocaliva) Intercept Pharmaceuticals Full submission 6/03/2017 2/05/2017 12/06/2017
obinutuzumab (Gazyvaro) Roche Full submission 5/12/2016 7/02/2017 13/03/2017
pembrolizumab (Keytruda) - 1st Line NSCLC MSD Full submission 3/04/2017 Q2 2017 Q3 2017
pertuzumab (Perjeta) Roche Resubmission 6/02/2017 2/05/2017 12/06/2017
selexipag (Uptravi) Actelion Pharmaceuticals UK Ltd Full submission 6/03/2017 6/06/2017 10/07/2017
stiripentol (Diacomit) BIOCODEX Resubmission 1/05/2017 Q3 2017 Q3 2017
trastuzumab emtansine (Kadcyla) Roche Resubmission 5/12/2016 7/03/2017 10/04/2017
venetoclax (Venclyxto) AbbVie Ltd Full submission 1/05/2017 Q3 2017 Q3 2017

Non-PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
ustekinumab (Stelara) Janssen-Cilag Ltd Full submission 1/05/2017 6/06/2017 10/07/2017
adalimumab (Humira) AbbVie Ltd Abbreviated Submission N/A 2/05/2017 12/06/2017
aprepitant (Emend) MSD Full submission 3/04/2017 2/05/2017 12/06/2017
aprepitant (Emend) MSD Abbreviated Submission N/A 6/06/2017 10/07/2017
belimumab (Benlysta) GlaxoSmithKline UK Ltd Resubmission 6/03/2017 4/04/2017 8/05/2017
budesonide-formoterol (Symbicort SMART) AstraZeneca UK Ltd Abbreviated Submission N/A 2/05/2017 12/06/2017
ciprofloxacin/dexamethasone (Cilodex) Novartis Pharmaceuticals UK Ltd Abbreviated Submission N/A 6/06/2017 10/07/2017
daclizumab (Zinbryta) Biogen Idec Ltd Full submission 6/02/2017 7/03/2017 10/04/2017
dolutegravir (Tivicay) ViiV Healthcare/GSK Abbreviated Submission N/A 6/06/2017 10/07/2017
empaglifozin linagliptin fixed-dose combination (Glyxambi) Boehringer Ingelheim Ltd Abbreviated Submission N/A 4/04/2017 8/05/2017
emtricitabine/tenofovir disoproxil fumarate (Truvada) Gilead Sciences Ltd Full submission 6/02/2017 7/03/2017 10/04/2017
glycopyrronium bromide (Sialanar) Proveca Limited Abbreviated Submission N/A 6/06/2017 10/07/2017
insulin aspart (Faster Aspart) Novo Nordisk Ltd Abbreviated Submission N/A 7/03/2017 10/04/2017
ixekizumab (Taltz) Eli Lilly and Company Ltd Full submission 6/02/2017 7/03/2017 10/04/2017
micronised progesterone (Utrogestan) Besins Healthcare (UK) Ltd Full submission 6/03/2017 4/04/2017 8/05/2017
nepafenac (Nevanac) Alcon Laboratories UK Ltd Abbreviated Submission 6/02/2017 7/03/2017 10/04/2017
reslizumab (Cinqaero) Teva UK Limited Full submission 6/03/2017 4/04/2017 8/05/2017
saxagliptin - dapagliflozin (Qtern) AstraZeneca UK Ltd Abbreviated Submission N/A 6/06/2017 10/07/2017
ticagrelor (Brilique) AstraZeneca UK Ltd Full submission 6/02/2017 7/03/2017 10/04/2017

Medicines with advice withheld pending product availability

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
dinutuximab (Unituxin) United Therapeutics Full submission 31/10/2015 6/01/2016 TBC
oritavancin (Orbactiv) The Medicines Company Full submission 2/11/2015 1/12/2015 TBC

Back